Methods-Analysis of data from children (<16 years at ART initiation) at South African ART sites at which CD4 count/percent and HIV-RNA monitoring are performed 6-monthly. Incomplete virological suppression (IVS) was defined as failure to achieve ≥1 HIV-RNA ≤400 copies/mL between 6 and 15 months on ART and viral rebound (VR) as confirmed HIV-RNA ≥5000 copies/ mL in a child on ART for ≥18 months who had achieved suppression during the first year on treatment. Conclusion-Current immunological criteria are unable to correctly identify children failing ART virologically. Improved access to viral load testing is needed to reliably identify virological failure in children.
Introduction
Poor access to viral load testing in resource-limited settings results in reliance on immunological criteria to identify treatment failure in patients on antiretroviral therapy (ART). Studies in adults have shown limited value of immunological criteria to detect virological failure (VF) , Mee et al. 2008 , Badri et al. 2008 . While low sensitivity of immunological criteria for identifying VF could result in delayed switching to second-line treatment with accumulation of resistance mutations, low positive predictive value (PPV) may incorrectly identify patients as needing second-line treatment when they are virologically suppressed. The few paediatric studies of diagnostic accuracy of immunological criteria for VF are limited by small cohort size and/or VF definition based on single elevated HIV-RNA measurements (Ruel et al. 2010 , Jittamala et al. 2009 , Emmett et al. 2010 . We analysed data from routine pediatric ART clinics to determine the diagnostic accuracy of WHO (2006 WHO ( , 2010 and United States Department of Health and Human Services (DHHS) 2008 (National Institutes of Health 2008) criteria for immunological failure for identifying (i) incomplete viral suppression during the first year on ART and (ii) confirmed viral rebound.
Methods
Data was collected prospectively from ART-naïve children (<16 years at ART start) initiating ≥3 antiretrovirals at South African sites participating in IeDEA-Southern Africa (IeDEA-SA, see www.iedea-sa.org), all of which had CD4 and HIV-RNA measurements performed 6-monthly. The characteristics of these sites have been described previously (Davies et al. 2009 ). Each site has institutional ethical approval to contribute data to IeDEA analyses.
HIV-RNA was measured using Amplicor 1.5 (Roche Diagnostics) or NucliSens EasyQ assays (bioMerieux), with good comparability (Stevens et al. 2005) . CD4 measurements were performed using standard dual platform flow cytometry or the single platform PanLeucogated method (Glencross et al. 2008) . We defined incomplete virological suppression (IVS) as failure to achieve ≥1 HIV-RNA ≤400 copies/mL between 6 and 15 months on ART and viral rebound (VR) as confirmed HIV-RNA ≥5000 copies/mL in a child on ART for ≥18 months whose HIV-RNA had suppressed during the first year on treatment. We examined the following immunological criteria: WHO 2010: No definition for children <2 years; CD4%<10% or CD4<200 cells/mm 3 (age 2-4 years); CD4<100 cells/ mm 3 (age ≥5 years) (WHO 2010 ). WHO 2006 No definition for children <1 year; CD4%<15% (age 1-2 years); CD4%<10% (age 3-4 years); CD4<100 cells/mm3 (age ≥5 years) (WHO 2006) . DHHS: During first year on ART: <5 percentage point CD4% increase from baseline (CD4%<15 and age <5 years at baseline) or <50 cells/mm 3 CD4 increase from baseline (CD4<200 cells/mm 3 and age ≥5 years at baseline); decline of CD4% by 5 percentage points from previous value, confirmed at subsequent measurement (<365 days after first low value) (any age); return of CD4 count ≤baseline value (age ≥5 years at baseline) (National Institutes of Health 2008).
For IVS, we assessed the diagnostic accuracy of never achieving a CD4 above the immunological thresholds between 6 and 15 months on ART for identifying a child who never had HIV-RNA ≤400 copies/mL during the same period. Only children followed up for ≥1 year with ≥1 HIV-RNA measurement between 6 and 15 months were included. For VR, CD4 and HIV-RNA measurements were carried forward for up to 3 months where tests were performed asynchronously. For each unique paired CD4 and HIV-RNA measurement, we determined the diagnostic value of CD4-based criteria for VR, using robust standard errors to account for multiple measures per patient. Immunological results for which there was still no concurrent virological diagnosis after carrying forward results, were not evaluated. Further, the last immunological result before the end of follow-up/data base closure was excluded to ensure that there was sufficient follow-up to for a confirmatory low viral load measurement to have been done. Separate sensitivity analyses were performed requiring either consecutive (within 365 days) CD4 measurements meeting immunological criteria or using an HIV-RNA threshold of 1000 copies/mL to define confirmed VR.
Results
Of 3640 children with ≥1 year of follow-up, 3115 (86%) had ≥1 HIV-RNA measurement between 6 and 15 months on ART. At ART initiation, median (interquartile range (IQR)) age was 48 (20-84) months. Most children were severely ill at ART initiation: 81% had WHO-defined severe immune suppression (n=2911) The accuracy of immunological criteria for identifying VR was assessed in 2513 children with at least ≥18 months follow-up on ART whose HIV-RNA had suppressed during the first year on treatment. The cumulative probability of viral rebound in the following 2 years (by 42 months since ART start) was 5.5% (95% CI: 4.2-7.1). Requiring consecutive CD4 counts to meet immunological criteria increased PPV only slightly at the expense of sensitivity, without any improvement in the area under the receiver operating characteristic curve (Table 1 ( 
Discussion
In this large longitudinal study we found that sensitivity and PPV were low for identifying VF using WHO and DHHS immunological criteria. For example, using confirmed HIV-RNA ≥5000 copies/mL after initial virological suppression to define VR, sensitivity was only 4% using either WHO 2006 or 2010 criteria. Fewer than half of children meeting WHO 2006/2010 criteria would have HIV-RNA ≥5000 copies/mL.
These results concur with those of previous small studies from resource-limited settings. Among 116 children in Uganda 20 (17%) had sustained viraemia (≥400 copies/mL) beyond 24 weeks on ART (Ruel et al. 2010) . Only 2 of these ever met WHO 2006 immunological criteria, and did so after >550 days of viraemia, while none met WHO 2010 criteria (Ruel et al. 2010) . Similarly, in a cross-sectional study of 206 children in Tanzania on ART for a median duration of 2.4 years, 32% had a single HIV-RNA ≥400 copies/mL (Emmett et al. 2010 ). WHO 2006 clinical and immunological failure criteria combined had a PPV of 100% but identified only 3.5% of children with HIV-RNA ≥400 copies/mL (Emmett et al. 2010 ).
In Thailand, the sensitivity and PPV of DHHS immunological criteria for identifying children with a single HIV-RNA >1000 copies/mL was 15% and 16% respectively (Jittamala et al. 2009 ).
The poor sensitivity of immunological criteria for identifying VF is disappointing, however perhaps an even greater concern is preventing the incorrect diagnosis of treatment failure in a virologically suppressed child, with unnecessary switch to second-line treatment, hence the importance of PPV. While PPV reached 89% for identifying VR ≥1000 copies/mL using a confirmed CD4 value meeting WHO 2010 criteria, given that the WHO 2010 guidelines HIV-RNA threshold for switching to second-line is 5000 copies/ml, in most instances the number of false positives using immunological criteria is unacceptably high. Further, absence of immunological failure on ART provides no assurance that a child is virologically suppressed and not accumulating resistance mutations, and even high CD4 thresholds (e.g. DHHS criteria) have low sensitivity for VF (PENPACT1 Study Team 2011). Improved access to VL monitoring both to assess adherence and identify VF is therefore needed (Ford & Calmy 2010 , Wilson et al. 2009 ).
There are several limitations to this analysis of routinely collected data. Missing baseline CD4 values limited evaluation of DHHS criteria. Baseline CD4 values are often unavailable to clinicians if children initiate ART on clinical criteria, records are lost or a child changes treatment site after ART initiation, highlighting the value of simple criteria using current or recent measurements. The accuracy of WHO 2006 and 2010 criteria could not be evaluated in children <1 and <2 years old respectively. Work-up bias may occur if either the reference (HIV-RNA) or index (CD4) tests are not applied consistently (Whiting et al. 2004 ). In particular, rigorous confirmation of low CD4 values is seldom done in South Africa, due to access to HIV-RNA measurements to diagnose treatment failure. Exclusion of intercurrent illness as a cause of low CD4, as advised in WHO guidelines (WHO 2010), was not possible due to limited data on episodes of clinical illness. Immunological criteria may have performed better if only low CD4 counts not explained by intercurrent illness had been considered. PPV is dependent on the VF incidence in different programs, however the incidence in this cohort was similar to that of other studies (Davies et al. 2011 , Jittamala et al. 2009 , Kamya et al. 2007 ).
In summary, our results suggest that current immunological criteria are unable to correctly identify children failing ART virologically. Improved access to viral load testing appears to be the only feasible approach at this stage for reliably identifying VF in children on ART. There are several existing technologies for the measurement of viral load (Stevens and Marshall 2010) 
